Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer

Kathleen N. Moore; Antoine Angelergues; Gottfried E. Konecny; Yolanda García García; Susana Banerjee; Domenica Lorusso; Jung‐Yun Lee; John W. Moroney; Nicoletta Colombo; A. Roszak; Jacqueline M. Tromp; Tashanna Myers; Jeong‐Won Lee; Mario Beiner; Casey Cosgrove; David Cibula; Lainie P. Martin; Renaud Sabatier; Joseph Buscema; Purificación Estévez-García; Lan Coffman; Shibani Nicum; Linda Duska; Sandro Pignata; Fernando Gálvez; Yuemei Wang; Michael Method; Anna Berkenblit; Diana Bello Roufai; Toon Van Gorp

doi:10.1056/nejmoa2309169

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

Among participants with platinum-resistant, FRα-positive ovarian cancer, treatment with MIRV showed a significant benefit over chemotherapy with respect to progression-free and overall survival and objective response. (Funded by ImmunoGen; MIRASOL ClinicalTrials.gov number, NCT04209855.).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Moore et al. (2023) studied this question.

synapsesocial.com/papers/69dbda929e6f14d6f16846e9 https://doi.org/10.1056/nejmoa2309169

View Full Paper

Ask AI

Bookmark

Share

Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer

Ask about this paper

Abstract

Discussion

Cite This Study

Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading